Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors

NCT01661400 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Glioma
Neuroectodermal Tumors, Primitive
Wilms Tumor
Rhabdomyosarcoma
Sarcoma, Ewing
Osteosarcoma
Retinoblastoma

Interventions

DRUG: Metronomic Cyclophosphamide
DRUG: Thalidomide

Sponsor

Washington University School of Medicine